Trial · NCT03420781
Adverse events390
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 390
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Urinary tract infection | Infections and infestations | Treatment Period: Placebo | 13 | 235 | |
| other | Urinary tract infection | Infections and infestations | Treatment Period: Relamorelin 10 μg | 16 | 231 | |
| other | Urinary tract infection | Infections and infestations | Randomized Withdrawal Period: Placebo Then Relamorelin 10 μg | 0 | 91 | |
| other | Urinary tract infection | Infections and infestations | Randomized Withdrawal Period: Relamorelin 10 μg Then Relamorelin 10 μg | 0 | 59 | |
| other | Urinary tract infection | Infections and infestations | Randomized Withdrawal Period: Relamorelin 10 μg Then Placebo | 0 | 43 | |
| other | Hyperglycaemia | Metabolism and nutrition disorders | Treatment Period: Placebo | 7 | 235 | |
| other | Hyperglycaemia | Metabolism and nutrition disorders | Treatment Period: Relamorelin 10 μg | 12 | 231 | |
| other | Hyperglycaemia | Metabolism and nutrition disorders | Randomized Withdrawal Period: Placebo Then Relamorelin 10 μg | 0 | 91 | |
| other | Hyperglycaemia | Metabolism and nutrition disorders | Randomized Withdrawal Period: Relamorelin 10 μg Then Relamorelin 10 μg | 0 | 59 | |
| other | Hyperglycaemia | Metabolism and nutrition disorders | Randomized Withdrawal Period: Relamorelin 10 μg Then Placebo | 0 | 43 | |
| serious | Coronary artery disease | Cardiac disorders | Treatment Period: Placebo | 3 | 235 | |
| serious | Coronary artery disease | Cardiac disorders | Treatment Period: Relamorelin 10 μg | 1 | 231 | |
| serious | Coronary artery disease | Cardiac disorders | Randomized Withdrawal Period: Placebo Then Relamorelin 10 μg | 0 | 91 | |
| serious | Coronary artery disease | Cardiac disorders | Randomized Withdrawal Period: Relamorelin 10 μg Then Relamorelin 10 μg | 0 | 59 | |
| serious | Coronary artery disease | Cardiac disorders | Randomized Withdrawal Period: Relamorelin 10 μg Then Placebo | 0 | 43 | |
| serious | Supraventricular extrasystoles | Cardiac disorders | Treatment Period: Placebo | 0 | 235 | |
| serious | Supraventricular extrasystoles | Cardiac disorders | Treatment Period: Relamorelin 10 μg | 1 | 231 | |
| serious | Supraventricular extrasystoles | Cardiac disorders | Randomized Withdrawal Period: Placebo Then Relamorelin 10 μg | 0 | 91 | |
| serious | Supraventricular extrasystoles | Cardiac disorders | Randomized Withdrawal Period: Relamorelin 10 μg Then Relamorelin 10 μg | 0 | 59 | |
| serious | Supraventricular extrasystoles | Cardiac disorders | Randomized Withdrawal Period: Relamorelin 10 μg Then Placebo | 0 | 43 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03420781/events